Compare Atlassian Corporation PLC (TEAM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs BIO-TECHNE Corp — how do they compare? Atlassian Corporation PLC trades at $155.63 (market cap $38.54B), while BIO-TECHNE Corp trades at $72.06 (market cap $11.24B). The key difference: Atlassian Corporation PLC is far larger — about 3.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| TEAM | TECH | |
|---|---|---|
Market Cap | $38.54B | $11.24B |
Sector | Technology | Health |
52-Week High | $182.36 | $72.29 |
52-Week Low | $57.15 | $43.31 |
Enterprise Value | $38.53B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian Corporation (TEAM) surged 35.31% to $149.07 following a strong Q4 2026 earnings beat, with revenue up 28% year-over-year to $1.77 billion and cloud revenue accelerating to 31%. The stock is trading near its pivot point of $148, with bullish technical signals from moving averages but overbought RSI readings. Analysts maintain a strong buy consensus with a $161.93 price target, citing enterprise deal expansion and AI platform adoption as key growth drivers.
Outlook remains positive due to robust revenue growth and margin improvement, but risks include high valuation multiples (P/S 5.9, EV/EBITDA 178.27) and persistent net losses. Investors should weigh the company's cloud momentum against profitability challenges and macroeconomic uncertainty impacting software demand.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
